Steep Hill Inc AI Stock Analysis
Want to see TSE:GPIN full AI Analyst Report?
Steep Hill Inc (GPIN) AI Stock Analysis
Steep Hill Inc
(CNQX:GPIN)
Poor financials from revenue absence and cash burn dominate as key risk, tempered by attractive low P/E valuation and stable technicals; score reflects high-risk early-stage pharma potential.
Steep Hill Inc (GPIN) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 889.83K
- Dividend Yield
- ―
- Average Volume (3M)
- 16.23K
- Price to Earnings (P/E)
- 0.4
- Beta (1Y)
- 0.83
- Revenue Growth
- ―
- EPS Growth
- -150.05%
- Country
- Canada
- Employees
- 6
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Drug Manufacturers - Specialty & Generic
Steep Hill Inc Business Overview & Revenue Model
Company Description
Steep Hill Inc., a cannabis science and technology company, provides laboratory testing, quality assurance, and data analytics services in Canada and the United States. It offers analytical testing services, such as cannabinoids, terpenes, pesticides...
How the Company Makes Money
null
Steep Hill Inc Financial Statement Overview
Summary
Weak income statement with no revenue and operating losses (score 25) drags down despite strong debt-free balance sheet (85) and modest cash flow (35); reflects early-stage pharma risks offset by equity strength.
Income Statement
25NegativeBalance Sheet
85Very PositiveCash Flow
35NegativeSteep Hill Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GPIN, the sentiment is Negative. The current price of 0.20 is above the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.22, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 87.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GPIN.
Steep Hill Inc Peers Comparison
Overall Rating
TSE:GPIN58Neutral
TSE:LABS55Neutral
TSE:INNO45Neutral
TSE:ATLE42Neutral
TSE:BNXT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| 58Neutral | CAD 8.11M | 0.39 | 19.51% | ― | ― | -150.05% | |
| 55Neutral | CAD 23.49M | -9.23 | -7.66% | ― | -9.31% | 66.84% | |
| 45Neutral | CAD 8.05M | -6.01 | -19.37% | ― | -19.20% | 42.54% | |
| 42Neutral | CAD 37.30M | -0.76 | -2099.75% | ― | -96.13% | 88.13% | |
| 38Underperform | CAD 32.66M | -2.91 | 142.79% | ― | ― | ― |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:GPIN | Steep Hill Inc | 0.20 | -0.13 | -39.21% | |
| TSE:ATLE | Willow Biosciences | 0.08 | -0.07 | -46.67% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.06 | -0.01 | -7.69% | |
| TSE:BNXT | Bionxt Solutions Inc | 0.24 | -0.45 | -65.22% | |
| TSE:INNO | Innocan Pharma Corporation | 1.79 | -11.00 | -86.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 30, 2025
